Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BYSI NASDAQ:ERNA NASDAQ:HYPD NASDAQ:INKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBYSIBeyondSpring$1.57$1.61$1.18▼$3.44$64.56M0.4115,996 shs40,089 shsERNAErnexa Therapeutics$11.99$6.80$3.18▼$91.54$13.98M1.885.01 million shs83,504 shsHYPDHyperion DeFi$3.62$3.66$1.40▼$17.18$54.87M2.57578,918 shs567,691 shsINKTMiNK Therapeutics$10.87$10.95$6.80▼$76.00$54.15M0.4728,693 shs41,794 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBYSIBeyondSpring0.00%+12.54%-5.54%+15.44%-9.20%ERNAErnexa Therapeutics0.00%-2.12%+150.18%+59.87%-85.98%HYPDHyperion DeFi0.00%+13.48%-13.19%+21.07%+104.52%INKTMiNK Therapeutics0.00%+8.27%-0.73%-5.23%+53.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBYSIBeyondSpring$1.57$1.61$1.18▼$3.44$64.56M0.4115,996 shs40,089 shsERNAErnexa Therapeutics$11.99$6.80$3.18▼$91.54$13.98M1.885.01 million shs83,504 shsHYPDHyperion DeFi$3.62$3.66$1.40▼$17.18$54.87M2.57578,918 shs567,691 shsINKTMiNK Therapeutics$10.87$10.95$6.80▼$76.00$54.15M0.4728,693 shs41,794 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBYSIBeyondSpring0.00%+12.54%-5.54%+15.44%-9.20%ERNAErnexa Therapeutics0.00%-2.12%+150.18%+59.87%-85.98%HYPDHyperion DeFi0.00%+13.48%-13.19%+21.07%+104.52%INKTMiNK Therapeutics0.00%+8.27%-0.73%-5.23%+53.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBYSIBeyondSpring 1.00SellN/AN/AERNAErnexa Therapeutics 2.00Hold$30.00150.21% UpsideHYPDHyperion DeFi 2.25Hold$5.8862.29% UpsideINKTMiNK Therapeutics 2.40Hold$35.00221.99% UpsideCurrent Analyst Ratings BreakdownLatest ERNA, BYSI, HYPD, and INKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026HYPDHyperion DeFi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/18/2026INKTMiNK Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.005/12/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026ERNAErnexa Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/7/2026ERNAErnexa TherapeuticsBrookline Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.004/24/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026ERNAErnexa Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/9/2026HYPDHyperion DeFi Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/1/2026INKTMiNK Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.003/30/2026HYPDHyperion DeFi Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/27/2026BYSIBeyondSpring Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBYSIBeyondSpring$1.75M36.89$0.11 per share13.82($0.74) per share-2.12ERNAErnexa Therapeutics$580K24.19N/AN/A$5.88 per share2.04HYPDHyperion DeFi$810K67.75N/AN/A$3.86 per share0.94INKTMiNK TherapeuticsN/AN/AN/AN/A($2.55) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBYSIBeyondSpring-$1.01M-$0.14N/AN/AN/AN/AN/A-14.00%8/12/2026 (Estimated)ERNAErnexa Therapeutics-$14.08M-$26.20N/AN/AN/AN/A-263.74%-151.16%8/12/2026 (Estimated)HYPDHyperion DeFi-$45.31M-$9.95N/A3.55N/AN/A-91.59%-73.08%N/AINKTMiNK Therapeutics-$12.49M-$2.84N/AN/AN/AN/AN/A-118.57%8/13/2026 (Estimated)Latest ERNA, BYSI, HYPD, and INKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026ERNAErnexa Therapeutics-$1.95-$6.95-$5.00-$6.95N/AN/A5/15/2026Q1 2026INKTMiNK Therapeutics-$0.77-$0.57+$0.20-$0.57N/AN/A5/13/2026Q4 2025BYSIBeyondSpring-$0.54-$0.05+$0.49-$0.05$8.77 millionN/A5/11/2026Q1 2026ERNAErnexa Therapeutics-$1.95-$6.95-$5.00-$6.95N/AN/A3/26/2026Q4 2025HYPDHyperion DeFiN/A-$7.76N/A-$7.76N/A$0.50 million3/25/2026Q4 2025BYSIBeyondSpring-$0.54-$0.05+$0.49-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBYSIBeyondSpringN/AN/AN/AN/AN/AERNAErnexa TherapeuticsN/AN/AN/AN/AN/AHYPDHyperion DeFiN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBYSIBeyondSpringN/A1.091.09ERNAErnexa TherapeuticsN/A2.892.89HYPDHyperion DeFi0.121.972.68INKTMiNK TherapeuticsN/A1.381.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBYSIBeyondSpring40.29%ERNAErnexa Therapeutics70.55%HYPDHyperion DeFi25.84%INKTMiNK Therapeutics2.87%Insider OwnershipCompanyInsider OwnershipBYSIBeyondSpring29.31%ERNAErnexa Therapeutics0.53%HYPDHyperion DeFi7.50%INKTMiNK Therapeutics22.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBYSIBeyondSpring8041.12 million29.07 millionOptionableERNAErnexa Therapeutics101.17 million1.16 millionNo DataHYPDHyperion DeFi4015.16 million14.02 millionNo DataINKTMiNK Therapeutics304.98 million3.86 millionNo DataERNA, BYSI, HYPD, and INKT HeadlinesRecent News About These CompaniesMiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Rating of "Hold" by BrokeragesMay 25 at 2:14 AM | americanbankingnews.comMiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology CommunicationsMay 20, 2026 | globenewswire.comMiNK Therapeutics (NASDAQ:INKT) Given "Buy" Rating at HC WainwrightMay 19, 2026 | americanbankingnews.comWe're Not Very Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn RateMay 18, 2026 | finance.yahoo.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2026 Earnings Call TranscriptMay 16, 2026 | insidermonkey.comMiNK (INKT) Q4 2025 Earnings Call TranscriptMay 16, 2026 | finance.yahoo.comMiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Strategic Advances and Financial ...May 16, 2026 | finance.yahoo.comWall Street Zen Upgrades MiNK Therapeutics (NASDAQ:INKT) to HoldMay 16, 2026 | americanbankingnews.comMiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call TranscriptMay 15, 2026 | seekingalpha.comMiNK Therapeutics Q1 Earnings Call HighlightsMay 15, 2026 | marketbeat.comMiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical ValidationMay 15, 2026 | globenewswire.comMiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical IllnessMay 14, 2026 | globenewswire.comMiNK presenteert data over iNKT-celtherapie agenT-797 op ASGCTMay 12, 2026 | nl.investing.comMiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026May 12, 2026 | globenewswire.comMiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy ProgramsMay 8, 2026 | globenewswire.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Given Consensus Recommendation of "Hold" by AnalystsApril 30, 2026 | marketbeat.comShort Interest in MiNK Therapeutics, Inc. (NASDAQ:INKT) Drops By 30.6%April 28, 2026 | marketbeat.comWhy MiNK Therapeutics, Inc.’s (INKT) Stock Is Up 7.23%April 25, 2026 | aaii.comAMiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal CancerApril 18, 2026 | markets.businessinsider.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of “Hold†by BrokeragesApril 5, 2026 | defenseworld.netDMiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026April 3, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 European Bank Stocks Nearing New 52-Week HighsBy Dan Schmidt | April 27, 2026Catching Falling Knives: Is It Time to Buy These Beaten-Down Stocks?By Dan Schmidt | May 11, 20262 Stocks to Watch as the Quantum Space Gets More CrowdedBy Nathan Reiff | May 3, 2026Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming DueBy Bridget Bennett | May 9, 20263 Emerging Markets ETFs to Maximize Exposure to High-Potential CountriesBy Nathan Reiff | May 4, 2026ERNA, BYSI, HYPD, and INKT Company DescriptionsBeyondSpring NASDAQ:BYSI$1.57 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.49 -0.08 (-5.10%) As of 05/22/2026 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Ernexa Therapeutics NASDAQ:ERNA$11.99 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$11.80 -0.19 (-1.58%) As of 05/22/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Hyperion DeFi NASDAQ:HYPD$3.62 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.66 +0.03 (+0.97%) As of 05/22/2026 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.MiNK Therapeutics NASDAQ:INKT$10.87 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$10.79 -0.08 (-0.75%) As of 05/22/2026 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
